NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 6,400 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 6,400 shares of the stock in a transaction dated Tuesday, July 28th. The stock was bought at an average cost of $4.95 per share, for a total transaction of $31,680.00. Following the acquisition, the insider directly owned 389,856 shares of the company’s stock, valued at approximately $1,929,787.20. This represents a 1.67% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were bought at an average price of $5.00 per share, with a total value of $17,050.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The shares were bought at an average cost of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Performance

Shares of NASDAQ NXTC opened at $5.02 on Thursday. The company has a market cap of $18.12 million, a P/E ratio of -0.29 and a beta of 1.42. The firm’s fifty day moving average is $3.66 and its two-hundred day moving average is $8.77. NextCure, Inc. has a 52-week low of $1.55 and a 52-week high of $15.74.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23. As a group, analysts forecast that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Finally, Wall Street Zen cut shares of NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NextCure has an average rating of “Hold” and a consensus price target of $19.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Cable Car Capital LP raised its stake in shares of NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of NextCure by 28.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after purchasing an additional 55,412 shares during the period. Ikarian Capital LLC purchased a new position in shares of NextCure during the 4th quarter worth about $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure during the 4th quarter worth about $3,363,000. Finally, Exome Asset Management LLC bought a new position in NextCure during the 4th quarter valued at about $2,341,000. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.